-
Kyle Bass Challenges Biogen Fumaderm Patent
Wednesday, April 22, 2015 - 12:58pm | 164A patent held by Biogen Inc (NASDAQ: BIIB) on its Fumaderm psoriasis treatment got challenged Tuesday by hedge fund manager and short seller Kyle Bass. Fumaderm, acquired by Biogen in 2006, accounted for $62 million of Biogen's $8.2 billion in 2014 product revenue. Biogen changed hands...